Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661402 | 0.89 | ALDH1A1 (0.60) | ADRA2CALDH1A1POLBHTTLTB4R2 | |
| SCHEMBL9716677 | 0.89 | ADRA2C (0.53) | ADRA2CALDH1A1POLBTSHRHPGD | |
| SCHEMBL9716701 | 0.88 | ADRA2C (0.55) | ADRA2CALDH1A1POLBHTTTSHR | |
| SCHEMBL6174036 | 0.88 | ADRA2C (0.51) | ADRA2CHPGDMEN1NPC1KMT2A | |
| SCHEMBL10349935 | 0.88 | MEN1 (0.56) | ADRA2CALDH1A1POLBTSHRMEN1 | |
| SCHEMBL10660695 | 0.88 | BACE1 (0.52) | ADRA2CALDH1A1HPGDMEN1NPC1 | |
| SCHEMBL6569544 | 0.88 | PKM (0.56) | ADRA2CALDH1A1TSHRHPGDMEN1 | |
| SCHEMBL6202036 | 0.86 | ADRA2C (0.57) | ADRA2CALDH1A1POLBHTTLTB4R2 | |
| SCHEMBL11503381 | 0.85 | ADRA2C (0.49) | ADRA2CALDH1A1POLBHTTTSHR | |
| SCHEMBL11503382 | 0.85 | ADRA2C (0.49) | ADRA2CALDH1A1POLBHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125772-B1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT (HU) | 2013-09-11 | — | — | EP | claimed |
| EP-2125772-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | Richter Gedeon NYRT (HU) | 2009-12-02 | — | — | EP | claimed |
| WO-2008078124-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT. (HU) | 2008-07-03 | — | — | WO | claimed |
| EP-1114815-B1 | Process to prepare taxol | UPJOHN CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | claimed |
| JP-2053755-A | — | — | None | — | — | JP | disclosed |
| JP-61267518-A | — | — | None | — | — | JP | disclosed |
| CN-119504598-A | Method for preparing azlactone self-coupling body by converting amino acid by using sulfur hexafluoride | 国网安徽省电力有限公司电力科学研究院 | 2025-02-25 | — | — | CN | disclosed |
| CN-107750245-B | (S) -CSA salts of S-ketamine, (R) -CSA salts of S-ketamine and methods for making S-ketamine | 詹森药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-28 | — | — | US | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| JP-S61267518-A | PENEM-OR CARBAPENEM-TYPE ANTIBIOTIC AGENT HAVING MITIGATED SIDE EFFECT | SANKYO CO LTD | 1986-11-27 | — | — | JP | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| EP-0022206-B1 | OPTICALLY PURE HETEROCYCLIC AMINO ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1984-02-15 | — | — | EP | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | STS, SRR, SRM | ADRA2C 118/4885ALDH1A1 2695/4885POLB 4005/4885 |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | ADRA2C 3087/4885ALDH1A1 947/4885POLB 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.